EMA Marketing Authorization and Product Overview

Viatris Inc. (ticker: VTRS), a global generics company, has received final marketing authorization from the European Medicines Agency (EMA) for Febuxostat Viatris, a treatment for gout and hyperuricemia. This approval was achieved by demonstrating bioequivalence to the original drug, Adenuric. Febuxostat Viatris can be used to treat chronic hyperuricemia with uric acid deposition, as well as to prevent hyperuricemia in patients with hematological malignancies at risk of tumor lysis syndrome. This approval marks a significant step for Viatris in strengthening its high-value generics portfolio in Europe.

Mechanism of Action of Xanthine Oxidase Inhibitors and Differentiation from Allopurinol

Febuxostat Viatris selectively inhibits xanthine oxidase, an enzyme that promotes uric acid synthesis in the body. Compared to allopurinol, the existing standard treatment, febuxostat offers a safety advantage by being relatively easy to administer even to patients with impaired renal function. Clinically, febuxostat has demonstrated superior efficacy compared to allopurinol, with a higher rate of achieving target uric acid levels (below 6.0 mg/dL). This provides a reliable alternative for patients who do not respond to or experience adverse effects from existing treatments.

Market Size of Hyperuricemia and Viatris' Market Entry Strategy

The global market for gout treatments is estimated at approximately $3 billion to $3.3 billion by 2026, and is expected to maintain a solid growth rate of over 6% annually due to aging populations and changes in dietary habits. Viatris plans to target the European market with a competitive price compared to the original drug, leveraging its large-scale production capacity and extensive distribution network. However, as European health authorities rigorously review the cost-effectiveness of drugs, price negotiations and reimbursement coverage will be implemented gradually. Securing price competitiveness during the initial market entry will be a key factor in expanding market share.

Competitive Landscape Following Patent Expiration of the Original Drug

Following the expiration of the patent for the original drug, Adenuric, the febuxostat generics market has become increasingly competitive with the entry of several global pharmaceutical companies. Viatris is adopting a strategy to secure a competitive advantage by combining simple price competition with the synergy of its diversified portfolio. This will provide significant positive healthcare benefits by substantially reducing the cost of treatment for patients with hyperuricemia. In the long term, the key to contributing to sales will be how quickly Viatris can absorb the market share of original drug developers such as Teijin and Takeda in response to the influx of competing generic products.